Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Độ tan chảy
61 °C (FAB fragment), 71 °C (whole mAb)
Dược Lực Học :
Used for the treatment of acute myeloid leukemia (AML), mylotarg binds to the CD33 antigen, which is expressed on the surface of leukemic cells in more than 80% of patients with AML. The CD33 antigen is not expressed on pluripotent hematopoietic stem cells or nonhematopoietic cells. This gives mylotarg the selectivity needed to target leukemic cells.
Cơ Chế Tác Dụng :
Recombinant humanized IgG4, kappa antibody conjugated with a cytotoxic antitumor antibiotic, calicheamicin, isolated from fermentation of a bacterium, Micromonospora echinospora ssp. calichensis. The antibody portion of Mylotarg binds specifically to the CD33 antigen, The anti-CD33 hP67.6 antibody is produced by mammalian cell suspension culture using a myeloma NS0 cell line. Gemtuzumab ozogamicin (trade name Mylotarg) was withdrawn in 2010 when a clinical trial showed the drug increased patient death and exhibited no advantages over traditional cancer therapies.
Mylotarg is directed against the CD33 antigen expressed by hematopoietic cells. Binding of the anti-CD33 antibody portion of Mylotarg with the CD33 antigen results in the formation of a complex that is internalized. Upon internalization, the calicheamicin derivative is released inside the lysosomes of the myeloid cell. The released calicheamicin derivative binds to DNA in the minor groove resulting in DNA double strand breaks and cell death.
Dược Động Học :
▧ Metabolism :
Most likely removed by opsonization via the reticuloendothelial system.
Độc Tính :
The most frequently reported toxicities are myelosuppression and hepatic veno-occlusive disorder.
Chỉ Định :
For treatment of CD33-positive acute myeloid leukemia in patients 60 and over who are not candidates for other chemotherapy.
Tương Tác Thuốc :
Avoid combination due to enhanced adverse effects of belimumab.
Avoid combination due to adverse effects of clozapine including the risk of agranulocytosis.
Monitor therapy due to enhanced adverse effects of immunosuppressants including the risk of infections.
Consider modifying therapy due to adverse effects of leflunomide including the risk of hematologic toxicity.
Avoid combination due to enhanced adverse effects of natalizumab including the risk of infections.
Avoid combination due to toxic effects of immunosuppressants.
Consider therapy modification due to enhanced immunosuppressive effect.
Monitor therapy due to reduced therapeutic effect of sipuleucel-t.
Avoid combination of adverse effects of immunosuppressants.
Avoid combination due to enhancement of immunosuppressants.
Monitor therapy due to enhanced neutropenic effect of immunosuppressants.
Liều Lượng & Cách Dùng :
Injection, powder, lyophilized, for solution - Intravenous
Tài Liệu Tham Khảo Thêm
National Drug Code Directory